What is Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf)?

Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) is a combination of two HER2/neu receptor antagonists and an endoglycosidase-hyaluronidase enzyme for the treatment of early-stage and metastatic HER2-positive breast cancer, as measured by a companion diagnostic test approved by the U.S. Food and Drug Administration (FDA) Phesgo is initially used in combination with chemotherapy. After the chemotherapy regimen is completed, the doctor will advise the patient to subcutaneously inject Phesgo into the thigh at home.

Phesgo is suitable for use in combination with intravenous chemotherapyAs part of a complete treatment plan for early breast cancer (EBC), it can be used as a neoadjuvant treatment for adult patients with HER2-positive, locally advanced, inflammatory or early breast cancer (larger than 2cm in diameter or lymph node positive). It can also be used as an adjuvant treatment for adult breast cancer patients with a high risk of recurrence of HER2-positive early cancer. Phesgois also indicated in combination with docetaxel (docetaxel) for the treatment of adult patients with HER2-positive metastatic breast cancer (MBC) who have not previously received anti-HER2 therapy or chemotherapy for metastatic disease.

Phesgo product labels include a boxed warning advising healthcare professionals and patients of the potential risks of cardiomyopathy, embryo-fetal toxicity, and pulmonary toxicity. Common side effects include hair loss, nausea, diarrhea, anemia and fatigue. The original Phesgo drug is not marketed in the country and therefore cannot be included in medical insurance. Since Phesgo's original drug has been on the market overseas for a short time, there is less price and other related information. For specific prices and drug information, please consult Yaode's medical consultant.